Clinical characteristics of non-CAD and CAD groups with and without AF
| Non-CAD group | CAD group | |||||
|---|---|---|---|---|---|---|
| AF (n=76) | Non-AF (n=500) | p Value | AF (n=35) | Non-AF (n=539) | p Value | |
| Age (years) | 70.7±8.5 | 67.6±13.1 | 0.046 | 72.3±8.5 | 69.4±11.5 | 0.126 |
| Sex (male) | 46 (60.5) | 297 (59.5) | 0.868 | 26 (74.3) | 403 (75.2) | 0.090 |
| BMI (kg/m2) | 25.1±4.2 | 24.6±4.3 | 0.349 | 23.3±4.5 | 24.3±3.7 | 0.154 |
| Smoking | 42 (56.8) | 258 (55.5) | 0.838 | 25 (71.4) | 323 (64.1) | 0.380 |
| HT | 51 (67.1) | 306 (65.7) | 0.806 | 25 (71.4) | 369 (72.2) | 0.920 |
| DM | 23 (30.3) | 157 (33.8) | 0.540 | 12 (34.3) | 216 (42.4) | 0.345 |
| DL | 27 (35.5) | 229 (49.6) | 0.023 | 18 (51.4) | 308 (60.8) | 0.276 |
| UA (mg/dL) | 6.3±1.6 | 5.9±1.8 | 0.054 | 6.7±2.7 | 5.9±1.7 | 0.007 |
| eGFR (mL/min/1.73m2) | 56.5±20.1 | 68.7±23.8 | <0.001 | 54.0±24.9 | 64.7±35.6 | 0.041 |
| BNP (pg/mL) | 144.3 (74.4-437.3) | 33.8 (14.5-92.1) | <0.001* | 168.4 (52.8-687.9) | 49.0 (19.3-123.1) | <0.001* |
| LDL (mg/dL) | 98.3±30.9 | 106.1±32.1 | 0.072 | 103.9±27.6 | 110.4±33.7 | 0.315 |
| HbA1c (%) | 6.3±1.1 | 6.2±1.2 | 0.356 | 6.3±1.1 | 6.4±1.4 | 0.746 |
| β blocker | 36 (48.0) | 102 (22.7) | <0.001 | 14 (40.0) | 121 (24.3) | 0.039 |
| ACEI/ARB | 36 (48.0) | 193 (42.6) | 0.383 | 18 (51.4) | 224 (45.0) | 0.459 |
| Statin | 15 (20.3) | 187 (41.5) | <0.001 | 14 (40.0) | 256 (51.4) | 0.192 |
| Nicorandil | 7 (9.6) | 69 (15.3) | 0.1987 | 9 (25.7) | 161(32.4) | 0.413 |
Data are given as the mean±SD or medians (IQRs), or number of patients with percentage in brackets.
*Kruskal-Wallis test.
ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers; AF, atrial fibrillation; BMI, body mass index; BNP, B-type natriuretic peptide; CAD, coronary artery disease; DL, dyslipidemia; DM, diabetes mellitus; eGFR, estimated glomerular filtration ratio; HT, hypertension; LDL, low-density lipoprotein cholesterol; UA, uric acid.